125712-98-3

Upstream product

• 125712-97-2 (S)-5-(2,2-Dimethyl-4,6-dioxo-[1,3]dioxan-5-ylidene)-pyrrolidine-2-carboxylic acid methyl ester 
• 100-51-6 benzyl alcohol 
• 140-11-4 Benzyl acetate 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 98-79-3 L-Pyroglutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 173142-47-7 methyl (2S)-5-methoxy-3,4-dihydro-2H-pyrrole-2-carboxylate 

Downstream Products

• 229640-43-1 phenylmethyl 3-(8-hydroxy-5-oxo-3-(benzyloxycarbonyl)-1,2,3-trihydroindolizin-6-yl)propanoate 
• 125659-61-2 (S)-6-(2-Methoxycarbonyl-ethyl)-5-oxo-1,2,3,5,6,7-hexahydro-indolizine-3,8-dicarboxylic acid 8-benzyl ester 3-methyl ester 
• 125659-62-3 (S)-6-(2-Methoxycarbonyl-ethyl)-5-oxo-1,2,3,5-tetrahydro-indolizine-3,8-dicarboxylic acid 8-benzyl ester 3-methyl ester 
• 87896-52-4 (-)-A58365A 
• 125659-60-1 (S)-6-(2-Carboxy-ethyl)-5-oxo-1,2,3,5,6,7-hexahydro-indolizine-3,8-dicarboxylic acid 8-benzyl ester 3-methyl ester 

Relevant academic research and scientific papers

COMPOUNDS USEFUL AS FACTOR XIA INHIBITORS

The present invention is directed to Factor XIa inhibitors, tautomers, stereoisomers, isotopologues, and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and / or prophylaxis of thromboembolic disorders, inflammatory disorders, and diseases or conditions in which plasma kallikrein activity is implicated.